Theravance Biopharma, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2012 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Theravance Biopharma, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2012 to 2023.
  • Theravance Biopharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $4.96M, a 20.7% decline year-over-year.
  • Theravance Biopharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $21.4M, a 19.3% decline year-over-year.
  • Theravance Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $25.4M, a 36.1% decline from 2022.
  • Theravance Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $39.7M, a 36% decline from 2021.
  • Theravance Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $62.1M, a 1.45% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $25.4M -$14.4M -36.1% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-01
2022 $39.7M -$22.3M -36% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-01
2021 $62.1M -$915K -1.45% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-01
2020 $63M +$2.53M +4.18% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-01
2019 $60.5M +$9.14M +17.8% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $51.3M +$2.17M +4.41% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-26
2017 $49.1M +$7.98M +19.4% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-27
2016 $41.2M -$12.9M -23.8% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 $54.1M +$10.8M +25% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-28
2014 $43.2M +$20.8M +92.4% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-01
2013 $22.5M +$1.15M +5.41% Jan 1, 2013 Dec 31, 2013 10-K 2016-03-11
2012 $21.3M Jan 1, 2012 Dec 31, 2012 10-K 2015-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.